or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVO D -2.99 2.06
    NVS D 0.13 1.30
    RY C 2.18 1.15
    ABBV F 2.01 1.12

    Represented by ETF Holdings

    Keywords: Eye Care Products Pharmaceutical Active Pharmaceutical Ingredients Adalimumab Advanced Prostate Cancer Anemia Animal Health Anti Diabetic Drugs Antibiotics Asset Management Products Atopic Dermatitis Autoimmune Disease Bank Banking Biopharmaceutical Biotechnology Blood Cancers Blood Test Capital Markets Services Cash Management
    Industries: Drug Manufacturers - Major Banks - Global Biotechnology

    Recent News for iShares Paris-Aligned Climate MSCI World ex USA ETF & its Holdings

    Date Stock Title
    Nov 20 ABBV Unpacking the Latest Options Trading Trends in AbbVie
    Nov 20 NVO More companies covering weight loss drugs for their employees
    Nov 20 NVO Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
    Nov 20 NVO Is Novo Nordisk Stock a Buy Right Now?
    Nov 20 RY One-Year Grant Milestone Marks Actionable Progress in Physician Burnout Research
    Nov 20 NVO RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
    Nov 19 NVO Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints
    Nov 19 NVO Sector Update: Health Care Stocks Decline
    Nov 19 NVO Novo Nordisk Unusual Options Activity For November 19
    Nov 19 NVO Sector Update: Health Care Stocks Mixed Tuesday Afternoon
    Nov 19 ABBV Where Will AbbVie Be in 5 Years?
    Nov 19 ABBV ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
    Nov 19 RY Top TSX Dividend Stocks To Watch In November 2024
    Nov 19 NVS Novartis ranks first in 2024 Access to Medicine Index
    Nov 19 NVO Novo Erases 2024 Gain, Wiping Out $210 Billion in Value
    Nov 19 NVS Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
    Nov 19 NVO Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
    Nov 19 NVS Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
    Nov 19 NVO Employers Get Pressure to Pay for Drugs Like Wegovy
    Nov 19 ABBV RVPH: Year-End OLE Update
    The index is composed of large- and mid-cap developed market equities, excluding the U.S., that are selected and weighted so that, in the aggregate, the portfolio is compatible with the objectives of the Paris Agreement by following a decarbonization trajectory, reducing exposure to climate-related transition and physical risks and increasing exposure to companies favorably positioned for the transition to a low-carbon economy. The fund generally will invest at least 90% of its assets in the component securities of its index.
    Passive Management
    Back to the Main PABD Page...